Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Hajime Takashima"'
Autor:
Hajime Takashima, Atsushi Yoshimori, Eiji Honda, Tomonori Taguri, Jun Ozawa, Masaji Kasai, Satoshi Shuto, Dai Takehara
Publikováno v:
ACS Omega, Vol 6, Iss 40, Pp 26601-26612 (2021)
Externí odkaz:
https://doaj.org/article/2f136a2a8e164a58908361d488e302f5
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 3 (2022)
ABSTRACT Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat to public health requiring the development of novel therapies. TP0586532 is a novel non-hydroxamate LpxC inhibitor that inhibits the synthesis of lipopolysaccharides, which a
Externí odkaz:
https://doaj.org/article/2ed7d709838b4a44a9ffcf92f49f6486
Autor:
Kumiko Tsuihiji, Eiji Honda, Kanehisa Kojoh, Shizue Katoh, Tomonori Taguri, Atsushi Yoshimori, Hajime Takashima
Publikováno v:
Pharmaceuticals, Vol 15, Iss 12, p 1506 (2022)
Currently, various pharmaceutical modalities are being developed rapidly. Targeting protein–protein interactions (PPIs) is an important objective in such development. Cyclic peptides, because they have good specificity and activity, have been attra
Externí odkaz:
https://doaj.org/article/08221a0e1c484e92919013e466985320
Publikováno v:
The Journal of Antibiotics
UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is an essential enzyme in the biosynthesis of Lipid A, an active component of lipopolysaccharide (LPS), from UDP-3-O-acyl-N-acetylglicosamine. LPS is a major component of the cell surface of Gram-ne
Autor:
Iichiro Takata, Hirotoshi Okumura, Hajime Takashima, Ippei Yoshida, Kiyoko Fujita, Katsumasa Otake, Hiroyuki Sugiyama
Publikováno v:
The Journal of Antibiotics. 75:98-107
The emergence of multi-drug resistant pathogenic bacteria, especially Gram-negative bacteria, is a worldwide health problem. New antibiotics directed at previously unexplored targets are urgently needed to overcome resistance to existing antibiotic c
Autor:
Eiji Honda, Tomonori Taguri, Atsushi Yoshimori, Dai Takehara, Jun Ozawa, Masaji Kasai, Hajime Takashima, Satoshi Shuto
Publikováno v:
ACS Omega, Vol 6, Iss 40, Pp 26601-26612 (2021)
ACS Omega
ACS Omega
Protein–protein interactions (PPIs) are fundamentally important and challenging drug targets. Peptidomimetic molecules of various types have been developed to modulate PPIs. A particularly promising drug discovery strategy, structural peptidomimeti
Publikováno v:
Journal of Computational Chemistry. 42:956-969
A heterocyclic compound mS-11 is a helix-mimetic designed to inhibit binding of an intrinsic disordered protein neural restrictive silence factor/repressor element 1 silencing factor (NRSF/REST) to a receptor protein mSin3B. We apply a generalized en
Autor:
Kiyoko Fujita, Iichiro Takata, Ippei Yoshida, Yusuke Honma, Hirotoshi Okumura, Katsumasa Otake, Hajime Takashima, Hiroyuki Sugiyama
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 28(5)
TP0586532 is a novel non-hydroxamate UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) inhibitor. Pharmacokinetic/pharmacodynamic (PK/PD) indices and magnitude of index that correlated with the efficacy of TP0586532 were determined and used to esti
Autor:
Yuya Ogata, Harumi Kanazawa, Macias Alba, Norikazu Ohtake, Allan E. Surgenor, Iichiro Takata, Hajime Takashima, Walmsley David, Kiyoko Fujita, Hayley Angove, Kunihiko Iwamoto, Masashi Mima, Hiroyuki Sugiyama, Fumihito Ushiyama, Junya Yamagishi, Yousuke Yamada, Alan P. Robertson, Kosuke Hitaka, Koichiro Nakano, Hayato Watanabe, Atsushi Okada, Yohei Matsuda, Roderick E. Hubbard, Nozomi Tanaka-Yamamoto, Toru Yamaguchi-Sasaki, Risa Kurimoto-Tsuruta, Lisa Baker, Akihiro Tanaka, R. Harris
Publikováno v:
Journal of medicinal chemistry. 63(23)
UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a zinc metalloenzyme that catalyzes the first committed step in the biosynthesis of Lipid A, an essential component of the cell envelope of Gram-negative bacteria. The most advanced, disclosed Lp
Autor:
Yuya Ogata, Nozomi Tanaka-Yamamoto, Naoki Sasamoto, Iichiro Takata, Katsumasa Otake, Hajime Takashima, Yohei Matsuda, Haruhiro Yamashita, Mayumi Endo, Kiyoko Fujita, Kaori Ueki, Masashi Mima, Satoshi Tsuji, Hirotoshi Okumura, Hiroyuki Sugiyama, Fumihito Ushiyama, Risa Kurimoto-Tsuruta
Publikováno v:
Bioorganicmedicinal chemistry. 30
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly de